BeiGene Ltd Stock News

Zacks Investment Research upgraded shares of BeiGene (NASDAQ:BGNE) from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. Zacks Investment Research currently has $389.00 price objective on the stock. According to Zacks, BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The companys clinical-stage drug candidates include [] The post BeiGene (NASDAQ:BGNE) Rating Increased to Buy at Zacks Investment Research appeared first on ETF Daily News .

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have received an average recommendation of Buy from the ten ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokerages that []

The China National Medical Products Administration has approved BeiGene Ltd (NASDAQ: BGNE) / EUSA Pharma (UK) Ltd's Sylvant (siltuximab) for adult patients with multicentric Castleman disease (MC

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has approved SYLVANT(siltuximab for injection) f…

BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has approved SYLVANT(siltuximab for injection) for…

Established in 2010 in Beijing, BeiGen launched its IPO in Nasdaq in 2016 and in Hong Kong in 2018.

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene will present new clinical data on tislelizumab at ESMO IO Congress 2021, including results from RATIONALE 309 in nasopharyngeal can

The European Commission has approved BeiGene Ltd''s (NASDAQ: BGNE ) BRUKINSA (zanubrutinib) for Waldenström''s macroglobulinemia (WM). WM is a type of non-Hodgkin lymphoma. This rare blood cell cancer is characterized by an excess of abnormal white blood cells in the bone marrow. The approval covers adult WM patients who Full story available on Benzinga.com

California State Teachers Retirement System acquired a new position in BeiGene, Ltd. (NASDAQ:BGNE) during the second quarter, HoldingsChannel.com reports. The fund acquired 3,062 shares of the companys stock, valued at approximately $1,051,000. Several other institutional investors and hedge funds have also bought and sold shares of the stock. Parallel Advisors LLC boosted its holdings in []

The European Commission has approved BeiGene Ltd's (NASDAQ: BGNE) BRUKINSA (zanubrutinib) for Waldenström's macroglobulinemia (WM). WM is a type of non-Hodgkin lymphoma.

BeiGene Acquires 42-Acre Site From Lincoln Equities

EU approval follows recent approvals for BRUKINSAincluding U.S., China, Brazil, and Canada The approval is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene (N

BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces approval of BRUKINSA (zanubrutinib) in the European Union for treatment of adults with Waldenströms macroglobulinemia.